ENTA | Enanta Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.42 - 9.05
52 Week Range	8.00 - 17.80
Beta	0.60
Implied Volatility	121.21%
IV Rank	49.86%
Day's Volume	146,335
Average Volume	184,104
Shares Outstanding	21,194,300
Market Cap	191,808,415
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-03-21

Valuation
Profitability
Growth
Health
P/E Ratio	-1.66
Forward P/E Ratio	N/A
EPS	-5.46
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	145
Country	USA
Website	ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

ENTA's peers: GLUE, DSGN, HOWL, IKNA, STOK, CRNX, INBX, MRUS, LYEL, KRON, IPSC, EWTX, CCCC, MLYS, CGEM, THRX, RVMD, OMER, VCYT

*Chart delayed

Analyzing fundamentals for ENTA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ENTA Fundamentals page.

Watching at ENTA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ENTA Technicals page.